Liver TransplantationNCT07105085
Long-Term Outcomes of ABO-Incompatible Versus Compatible Living Donor Liver Transplantation
An observational study of Liver Transplantation and Liver Diseases, run by Seoung Hoon Kim.
Trial summary
This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients at a single high-volume transplant center in Korea. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Transplantation, Liver Diseases
- What is being tested?
- living donor liver transplantation
- Type of treatment
- Surgery or procedure
- How many people
- 511 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2012to 1 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: the patients who underwent living donor liver transplantation
Who may be able to join
- All adult patients who underwent LDLT at the study center from 2012 to 2022
Who cannot join
- Pediatric patients, deceased donor recipients, multi-organ transplants.
About this study
Official title: Long-Term Outcomes of ABO-Incompatible Versus Compatible Living Donor Liver Transplantation: A Single-Center Retrospective Study
This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients at a single high-volume transplant center in Korea.
The study aims to compare overall survival and the incidence of biliary complications.
Read the detailed description
This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients underwent LDLT between January 2012 and December 2022 at a single high-volume transplant center in Korea. Among them, 121 received ABO-I grafts using a rituximab-based desensitization protocol, while 390 underwent ABO-C LDLT. The study aims to compare overall survival and the incidence of biliary complications, as well as to identify risk factors specific to each group. This analysis provides insights into the long-term safety and efficacy of ABO-I LDLT in regions with low deceased donor organ availability.
- Conditions
- Liver Transplantation, Liver Diseases
- Being tested
- living donor liver transplantation
- Medical subject headings
- Liver Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
living donor liver transplantationProcedure or surgery
other intervention cannot be applied.
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of biliary complications
Statistical analyses are conducted to determine the incidence of biliary complication.
Measured: within 10 years post-transplantation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2025
- Study start1 Jan 2012
- Primary completion31 Dec 2022
- Study completion1 Jul 2025
Why it stopped: in order to get sufficient follow-up period and judged to be gather enough subjects
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 511 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seoung Hoon Kim
- Sponsor type
- Other government
- Responsible party
- Sponsor-investigator, Seoung Hoon Kim, National Cancer Center, Korea
- Investigators
- Seoung Hoon kim, MD, PhD, Principal investigator, National Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07105085
- Sponsor's protocol ID
- NCC2023-0110
- Status last verified
- Jul 2025
- First submitted
- 29 Jul 2025
- Last updated
- 5 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The data that support the findings of this study are not publicly available due to institutional and ethical restrictions but are available from the corresponding author on reasonable request and with permission from the institution.
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-Term Outcomes of ABO-Incompatible Versus Compatible Living Donor Liver Transplantation: A Single-Center Retrospective Study
- ClinicalTrials.gov ID
- NCT07105085
- Acronym / sponsor ID
- NCC2023-0110
- Conditions
- Liver Transplantation, Liver Diseases
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: in order to get sufficient follow-up period and judged to be gather enough subjects
- Enrolment
- 511 participants (actual)
- Lead sponsor
- Seoung Hoon KimOther government
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 1 Jul 2025 (actual)
- First posted
- 5 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients at a single high-volume transplant center in Korea.
The study aims to compare overall survival and the incidence of biliary complications.
Detailed description
This retrospective cohort study investigates the long-term outcomes of ABO-incompatible (ABO-I) versus ABO-compatible (ABO-C) living donor liver transplantation (LDLT). A total of 511 patients underwent LDLT between January 2012 and December 2022 at a single high-volume transplant center in Korea. Among them, 121 received ABO-I grafts using a rituximab-based desensitization protocol, while 390 underwent ABO-C LDLT. The study aims to compare overall survival and the incidence of biliary complications, as well as to identify risk factors specific to each group. This analysis provides insights into the long-term safety and efficacy of ABO-I LDLT in regions with low deceased donor organ availability.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- the patients who underwent living donor liver transplantation
Key inclusion criteria (1 listed)
- All adult patients who underwent LDLT at the study center from 2012 to 2022
Key exclusion criteria (1 listed)
- Pediatric patients, deceased donor recipients, multi-organ transplants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| living donor liver transplantationother intervention cannot be applied. | Procedure or surgery | – |
Primary outcome
Incidence of biliary complications
Time frame: within 10 years post-transplantation
Statistical analyses are conducted to determine the incidence of biliary complication.
Results and safety
The study was stopped early (reason given: in order to get sufficient follow-up period and judged to be gather enough subjects). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2025.
- Individual participant dataSharing planned: Undecided. The data that support the findings of this study are not publicly available due to institutional and ethical restrictions but are available from the corresponding author on reasonable request and with permission from the institution.
Related trials for Liver Transplantation
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
RecruitingPhase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Liver Transplant
RecruitingObservational study
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Seoung Hoon kim, MD, PhD principal investigator
National Cancer Center
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Transplantation and Liver Diseases, run by Seoung Hoon Kim.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 5 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: in order to get sufficient follow-up period and judged to be gather enough subjects). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of biliary complications (time frame: within 10 years post-transplantation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2025.